Consumer and Healthcare Provided Preferences for Adult Combination COVID-19 and Influenza Vaccines: Results from a Discrete Choice Study in France, Italy and Germany
Author(s)
Mariana Servin, NA1, Darshan Mehta, MBA, PhD2, John Crocker, MA3, Shivam Jindal, BTech3, Omer Ismail, BBA3, Nicolas Van de Velde, MBA, MSc, PhD1.
1Moderna, Inc, Cambridge, MA, USA, 2Moderna, Inc, Ca, MA, USA, 3Trinity Life Sciences, Waltham, MA, USA.
1Moderna, Inc, Cambridge, MA, USA, 2Moderna, Inc, Ca, MA, USA, 3Trinity Life Sciences, Waltham, MA, USA.
Presentation Documents
OBJECTIVES: Quantify consumer and healthcare providers (HCPs) preference for an adult combination vaccine for influenza and COVID-19 compared with standalone influenza and COVID-19 vaccines; and estimate the resulting impact on influenza and COVID-19 vaccine coverage rates (VCR) for adults in France, Italy, and Germany.
METHODS: A discrete-choice experiment (DCE) with hypothetical vaccine profile was conducted in each country. Each DCE included following attributes with varying levels: influenza only, combined influenza & COVID-19, vaccine composition, influenza immunogenicity and COVID-19 immunogenicity, tolerability (). The study population, recruited via an online panel, included consumers aged ≥18 years (FR: 256, DE: 256, IT: 250) and HCPs responsible for vaccination (FR: 80, DE: 78, IT: 80). Respondent data were weighted to reflect the population by age segment and to align influenza and COVID-19 VCR for 2023 - 2024. Respondent preferences from the DCE were used to estimate the change in influenza and COVID-19 coverage rates due to availability of a combined vaccine.
RESULTS: The mean age of the consumer sample was 53.9 years including male (62%) and female (38%) respondents. Consumers in all countries expressed preference for a combination vaccine; on average, 53% of consumers strongly preferred a combination vaccine, 23% strongly preferred individual vaccines, and 24% expressed no preference. The majority of HCPs demonstrated high likelihood to recommend a combination vaccine to patients (FR: 52%, DE: 57%, IT: 65%). Modelled preference shares projected that flu and COVID-19 VCR will likely increase because of availability of combination vaccine across markets (COVID VCR increase in percentage points - FR: 6%, DE: 7%, IT: 5%: FLU VCR increase in percentage points - FR: 5%, DE: 3%, IT: 3%)).
CONCLUSIONS: Results suggests that most consumers and HCPs preferred and recommended a combination flu+COVID-19 vaccine compared with standalone vaccines. Further, availability of a combination vaccine could help increase COVID-19 and flu VCR.
METHODS: A discrete-choice experiment (DCE) with hypothetical vaccine profile was conducted in each country. Each DCE included following attributes with varying levels: influenza only, combined influenza & COVID-19, vaccine composition, influenza immunogenicity and COVID-19 immunogenicity, tolerability (). The study population, recruited via an online panel, included consumers aged ≥18 years (FR: 256, DE: 256, IT: 250) and HCPs responsible for vaccination (FR: 80, DE: 78, IT: 80). Respondent data were weighted to reflect the population by age segment and to align influenza and COVID-19 VCR for 2023 - 2024. Respondent preferences from the DCE were used to estimate the change in influenza and COVID-19 coverage rates due to availability of a combined vaccine.
RESULTS: The mean age of the consumer sample was 53.9 years including male (62%) and female (38%) respondents. Consumers in all countries expressed preference for a combination vaccine; on average, 53% of consumers strongly preferred a combination vaccine, 23% strongly preferred individual vaccines, and 24% expressed no preference. The majority of HCPs demonstrated high likelihood to recommend a combination vaccine to patients (FR: 52%, DE: 57%, IT: 65%). Modelled preference shares projected that flu and COVID-19 VCR will likely increase because of availability of combination vaccine across markets (COVID VCR increase in percentage points - FR: 6%, DE: 7%, IT: 5%: FLU VCR increase in percentage points - FR: 5%, DE: 3%, IT: 3%)).
CONCLUSIONS: Results suggests that most consumers and HCPs preferred and recommended a combination flu+COVID-19 vaccine compared with standalone vaccines. Further, availability of a combination vaccine could help increase COVID-19 and flu VCR.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
PCR136
Topic
Patient-Centered Research
Disease
STA: Vaccines